R&D Strategies at Pharmaceutical Companies 2018

Language:
Japanese
Product Code No:
C59120700
Issued In:
2018/03
#of Pages:
277
Publication Cycle:
Other
Format:
PDF

Buy this research

Price:
130,000 yen ($1,233.28)(excluding consumption tax)
* Equivalent value in US$ (Today's rate : $1= 105.41 yen , 2019/08/25 Japan)

Coverage: (Product/service)

R&D Strategies at Pharmaceutical Companies

Research Target:

Pharmaceutical Companies

Research Content:

I   R&D Strategies at Pharmaceutical Companies and Actual Status and Perspectives of CRO and SMO

  1. R&D Strategies at Pharmaceutical Companies
  2. CRO Market Status and Perspectives
  3. SMO Market Status and Perspectives

II   R&D Strategies at Leading Pharmaceutical Enterprises

  1. Astellas Pharma Inc.
  2. AstraZeneca K.K.
  3. Eisai Co., Ltd.
  4. MSD K.K. a subsidiary of Merck & Co., Inc.,
  5. Otsuka Holdings Co., Ltd.
  6. ONO PHARMACEUTICAL CO., LTD.
  7. Kyowa Hakko Kirin Co., Ltd.
  8. GlaxoSmithKline K.K.
  9. Sanofi K.K.
  10. SHIONOGI & CO., LTD.
  11. DAIICHI SANKYO COMPANY, LIMITED
  12. Sumitomo Dainippon Pharma Co., Ltd.
  13. Takeda Pharmaceutical Company Limited.
  14. Mitsubishi Tanabe Pharma Corporation
  15. CHUGAI PHARMACEUTICAL CO., LTD.
  16. Eli Lilly Japan K.K.
  17. Boehringer Ingelheim Japan, Inc.
  18. Novartis Pharma K.K.
  19. Bayer Yakuhin, Ltd.
  20. Pfizer Japn, Inc.

III   Strategies of CRO/SMO Enterprises

  1. EPS Holdings, Inc. (EPS Corporation, EP-Mint Co., Ltd.)
  2. CAC Croit Corporation
  3. CMIC HOLDINGS Co., Ltd.
  4. BI Medical, Inc.
  5. Micron Inc.
  • Leading CRO Enterprises: 36 enterprises,
  • Leading SMO Enterprises: 35 enterprises

 

Buy this research

written in Japanese
Price:
130,000 yen ($1,233.28)(excluding consumption tax)
* Equivalent value in US$ (Today's rate : $1= 105.41 yen , 2019/08/25 Japan)